Prescribing Atypical Antipsychotics: What are the Risks?
The Carlat Psychiatry Report, Volume 7, Number 3, March 2009
https://www.thecarlatreport.com/newsletter-issue/tcprv7n3/
Issue Links: | Editorial Information
Topics: Antipsychotics
Michael Posternak, MD
Over the past several years, the use of antipsychotics has expanded dramatically. Aside from the traditional indication, schizophrenia, various members of this class have received FDA approval for bipolar mania, bipolar depression, major depression, and autism, and increasingly they are used off-label for anxiety, insomnia, and agitation.
You can't view details of this content, please login or buy subscription here
Michael Posternak, MD
Assistant Clinical Professor of Psychiatry Brown University School of Medicine
Dr. Posternak has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity. The author has disclosed that triidothyronine and methylphenidate have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression. Please consult product labeling for the approved usage of these drugs